Estimating the Cost of Immunoglobulin Replacement Therapy in Primary Immunodeficiency Patients

Authors Information
Article Notes and Dates
To Cite : Shabaninejad H, Asgharzadeh A, Rezaei N, Rezapour A. Estimating the Cost of Immunoglobulin Replacement Therapy in Primary Immunodeficiency Patients, Iran J Pediatr. 2017 ;27(4):e6294. doi: 10.5812/ijp.6294.
1. Background
2. Methods
3. Results
4. Discussion
  • 1. Bousfiha A, Picard C, Boisson-Dupuis S, Zhang SY, Bustamante J, Puel A, et al. Primary immunodeficiencies of protective immunity to primary infections. Clin Immunol. 2010; 135(2): 204-9[DOI][PubMed]
  • 2. Aghamohammadi A, Moin M, Rezaei N. History of primary immunodeficiency diseases in iran. Iran J Pediatr. 2010; 20(1): 16-34[PubMed]
  • 3. Borte S, Wang N, Oskarsdottir S, von Dobeln U, Hammarstrom L. Newborn screening for primary immunodeficiencies: beyond SCID and XLA. Ann N Y Acad Sci. 2011; 1246: 118-30[DOI][PubMed]
  • 4. Puck JM. Neonatal screening for severe combined immunodeficiency. Curr Opin Pediatr. 2011; 23(6): 667-73[DOI][PubMed]
  • 5. Aghamohammadi A, Mohammadinejad P, Abolhassani H, Mirminachi B, Movahedi M, Gharagozlou M, et al. Primary immunodeficiency disorders in Iran: update and new insights from the third report of the national registry. J Clin Immunol. 2014; 34(4): 478-90[DOI][PubMed]
  • 6. Rezaei N, Abolhassani H, Aghamohammadi A, Ochs HD. Indications and safety of intravenous and subcutaneous immunoglobulin therapy. Expert Rev Clin Immunol. 2011; 7(3): 301-16[DOI][PubMed]
  • 7. Peter JG, Chapel H. Immunoglobulin replacement therapy for primary immunodeficiencies. Immunotherapy. 2014; 6(7): 853-69[DOI][PubMed]
  • 8. Lucas M, Lee M, Lortan J, Lopez-Granados E, Misbah S, Chapel H. Infection outcomes in patients with common variable immunodeficiency disorders: relationship to immunoglobulin therapy over 22 years. J Allergy Clin Immunol. 2010; 125(6): 1354-1360 e4[DOI][PubMed]
  • 9. Shapiro RS. Why I use subcutaneous immunoglobulin (SCIG). J Clin Immunol. 2013; 33 Suppl 2-8[DOI][PubMed]
  • 10. Schroeder HJ, Dougherty CJ. Review of intravenous immunoglobulin replacement therapy trials for primary humoral immunodeficiency patients. Infection. 2012; 40(6): 601-11[DOI][PubMed]
  • 11. Soler-Palacin P, Gaso-Gago I, Fernandez-Polo A, Martin-Nalda A, Oliveras M, Martinez-Cutillas J, et al. Intravenous and subcutaneous immunoglobulin replacement: a two-way road. Optimizing healthcare quality in patients with primary immunodeficiencies. J Clin Immunol. 2014; 34(8): 1015-7[DOI][PubMed]
  • 12. Vultaggio A, Azzari C, Milito C, Finocchi A, Toppino C, Spadaro G, et al. Subcutaneous immunoglobulin replacement therapy in patients with primary immunodeficiency in routine clinical practice: the VISPO prospective multicenter study. Clin Drug Investig. 2015; 35(3): 179-85[DOI][PubMed]
  • 13. Membe SK, Ho C, Cimon K, Morrison A, Kanani A, Roifman CM. Economic assessment of different modalities of immunoglobulin replacement therapy. Immunol Allergy Clin North Am. 2008; 28(4): 861-74[DOI][PubMed]
  • 14. Martin A, Lavoie L, Goetghebeur M, Schellenberg R. Economic benefit of subcutaneous rapid push versus intravenous immunoglobulin infusion therapy in adult patients with primary immune deficiency. Allergy Asthma Clin Immunol. 2012; 8: 20[DOI]
  • 15. Ho C, Membe SK, Cimon K. An overview of subcutaneous vs. intravenous immunoglobulin for primary immunodeficiencies: systematic review and economic analysis. Canadian Agen Drugs Technol Health. 2008; 36: 1-8
  • 16. Liu Z, Albon E, Hyde C. The effectiveness and cost effectiveness of immunoglobulin replacement therapy for primary immunodeficiency and chronic lymphocytic leukaemia: a systematic review and economic evaluation. 2005;
  • 17. Abolhassani H, Sadaghiani MS, Aghamohammadi A, Ochs HD, Rezaei N. Home-based subcutaneous immunoglobulin versus hospital-based intravenous immunoglobulin in treatment of primary antibody deficiencies: systematic review and meta analysis. J Clin Immunol. 2012; 32(6): 1180-92[DOI][PubMed]
  • 18. Beaute J, Levy P, Millet V, Debre M, Dudoit Y, Le Mignot L, et al. Economic evaluation of immunoglobulin replacement in patients with primary antibody deficiencies. Clin Exp Immunol. 2010; 160(2): 240-5[DOI][PubMed]
  • 19. Igarashi A, Kanegane H, Kobayashi M, Miyawaki T, Tsutani K. Cost-minimization analysis of IgPro20, a subcutaneous immunoglobulin, in Japanese patients with primary immunodeficiency. Clin Ther. 2014; 36(11): 1616-24[DOI][PubMed]
  • 20. Shabaninejad H, Asgharzadeh A, Rezaei N, Rezapoor A. A Comparative Study of Intravenous Immunoglobulin and Subcutaneous Immunoglobulin in Adult Patients with Primary Immunodeficiency Diseases: A Systematic Review and Meta-Analysis. Expert Rev Clin Immunol. 2016; 12(5): 595-602[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiaion Alert via Google Reader

Cited By:

Iranian Journal of Pediatrics accepts terms & conditions of:

International Committee of Medical Journal Editors (ICMJE) Citedby Linking DOI enabled Crossref iThenticate COPE Cross Check